Dr Reddy’s warns public on spurious versions of 2DG

The company said 2DG was given emergency use approval in India for anti-C-19 therapeutic application.


Generic drugmaker, Dr Reddy’s Laboratories which had developed 2-deoxy-D-glucose (2DG) as an anti-C-19 drug in collaboration with the Defence Research and Development Organisation (DRDO), has warned the public against spurious or illegal products in the name of 2DG.

Giving hopes amid rising number of hospitalised C-19 patients needing external oxygen support in the second wave of coronavirus pandemic, Dr Reddy’s and DRDO have recently announced that antiviral drug was found to aid in speedy recovery and reduction of oxygen dependence for hospitalised patients.


Releasing the first batch of the antiviral drug 2DG on Monday, the companies said the drug accumulates in virus infected cells of the patient and prevents the growth of the virus by stalling the viral synthesis and energy production.

In a tweet late on Wednesday, the Hyderabad headquartered pharmaceutical firm said the orally administered powder is “not yet been launched into the market” and that the “price per sachet has not yet been announced.”

To read more articles on 2-DG, click here

The company said 2DG was given emergency use approval in India for anti-C-19 therapeutic application.

Dr Reddy’s urged the public to be “beware of agents selling spurious or illegal products in the name of 2DG” and also to be “beware of unverified messages relating to 2DG on social media and on WhatsApp.”

The drug firm said the commercial launch and supply of 2DG to major government and private hospitals is expected to commence in mid-June.

Further, the drugmaker also said the price is being determined with a view to making it accessible and affordable to as many patients as possible and will be announced soon.

“2DG is an oral antiviral drug that can be administered only upon prescription to hospitalized moderate to severe C-19 patients as adjunct (add on) therapy along with the existing standard of care,” said Dr Reddy’s Labs.

Also read:

NPPA fixes retail prices of 2 formulations

Bring Nutraceuticals for prevention of diseases under DCGI’s regulation: Experts to…

Baricitinib: BDR Pharma signs licensing agreement with Lilly

Optimus Pharma gets DCGI nod for Phase III trials of Molnupiravir

Black Fungus: AIIMS to develop Guidelines for treatment

NPPA directs Pulse Oximeter & Oxygen Concentrators to submit MRP

Subscribe for daily free updates on Telegram

Follow us on Facebook and Linkedin

For daily free updates on WhatsApp, click here

Enter your email address:

Delivered by FeedBurner